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Abstract: Only very little is know about the neurovascular niche after cardioembolic stroke. Three processes implicated 
in neurorepair: angiogenesis, neurogenesis and synaptic plasticity, would be naturally produced in adult brains, but also 
could be stimulated through endogen neurorepair phenomena. Angiogenesis stimulation generates new vessels with the 
aim to increase collateral circulation. Neurogenesis is controlled by intrinsic genetic mechanisms and growth factors but 
also ambiental factors are important. The leading process of the migrating neural progenitor cells (NPCs) is closely 
associated with blood vessels, suggesting that this interaction provides directional guidance to the NPCs. These findings 
suggest that blood vessels play an important role as a scaffold for NPCs migration toward the damaged brain region. DNA 
microarray technology and blood genomic profiling in human stroke provided tools to investigate the expression of 
thousands of genes. Critical comparison of gene expression profiles after stroke in humans with those in animal models 
should lead to a better understanding of the pathophysiology of brain ischaemia. Probably the most important part of early 
recovery after stroke is limited capacity of penumbra/infarct neurones to recover. It became more clear in the last years, 
that penumbra is not just passively dying over time but it is also actively recovering. This initial plasticity in majority 
contributes towards later neurogenesis, angiogenesis and final recovery. Penumbra is a principal target in acute phase of 
stroke. Thus, the origin of newly formed vessels and the pathogenic role of
 neovascularization and neurogenesis are 
important unresolved issues in our understanding
  of the mechanisms after stroke. Biomaterials for promoting brain 
protection, repair and regeneration are new hot target. Recently developed biomaterials can enable and increase the target 
delivery of drugs or therapeutic proteins to the brain, allow cell or tissue transplants to be effectively delivered to the brain 
and help to rebuild damaged circuits. These new approaches are gaining clear importance because nanotechnology allows 
better control over material-cell interactions that induce specific developmental processes and cellular responses including 
differentiation, migration and outgrowth.  
Keywords: Angiogenesis-neurogenesis-stroke-plasticity. 
1. BASIC MECHANISMS IN CARDIOEMBOLIC 
STROKE AND NEUROREPAIR  
  Atrial fibrillation is the most common cardiac 
arrhythmias, and a major cause of morbidity and mortality 
due to cardioembolic stroke. The left atrial appendage is the 
major site of thrombus formation in non-valvular atrial 
fibrillation. Loss of atrial systole in atrial fibrillation and 
increased relative risk of associated stroke point strongly 
toward a role for stasis of blood in left atrial thrombosis. 
However, thrombus formation is multifactorial, and much 
more than blood flow irregularities are implicated. The 
impact of thrombus formation, its later migration towards the 
smaller vessels, subsequent stroke leads to very different 
cellular and vascular responses as compared to stroke due to 
atherosclerosis. Only very little is know about the neuro-
vascular niche after cardioembolic stroke. Further, not much 
is known about the genetic basis for cardioembolic stroke. 
Only recently, an aging-suppressor gene, klotho, a candidate 
factor for vascular disease, its deficiency leads to impaired 
endothelium-dependent vasodilataion and imaipred   
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angiogenesis, was demostrated as a genetic risk factor for 
ischemic stroke caused by cardioembolism in Korean 
females [1].  
  There are three mechanisms related with brain plasticity 
(anatomical and functional changes of the central nervous 
system with the aim to improve functional recovery)[2, 3]:  
1)  Brain circuits regulation with the activation of parallel 
pathways for restore impaired functions; 
2)  Unmasking of silent functional pathways. 
Both would be short term mechanisms 
3)  A third mechanism, typical for longterm plasticity, 
would be the production of new sprouts and dendritic 
spines in survival neurons as well as formation of new 
synapses.  
  Therefore the three processes implicated in neurorepair 
(angiogenesis, neurogenesis and synaptic plasticity) would 
be naturally produced in adult brains and after different 
pathological situations, but also could be stimulated through 
endogen neurorepair phenomena with different pharmacolo-
gical treatments, always having in mind that the therapeutical 
window for neurorepair drugs is more wide than for neuro-
protective drugs, being able to treat almost all the stroke 
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generates new vessels with the aim to increase collateral 
circulation. Angiogenesis is also directly related with neuro-
genesis since blood supply is necessary for new neuronal 
survival and development [2, 3]. 
  Studying mechanisms regulating above processes will 
help to design future strategies in neurorepair.  
2. ANGIOGENESIS 
Nature Promotes Angiogenesis 
  After stroke, increased vascular remodelling is found in 
the areas of newly-born neuroblasts which migrate from the 
subventricular zone to the peri-infarcted cortex [5]. The 
presence of microvascular endothelial cells is important as 
they secrete growth factors and chemokines, which may 
support the survival of newly formed neurones. The adminis-
tration of human cord blood-derived CD34+ cells following 
stroke induces neovascularisation in the peri-infarcted cortex 
and increases neuroblast migration to the damaged tissue [6]. 
However, the role of the angiogenesis after stroke may be 
dual. Collateral revascularization may be important in deter-
mining patient recovery from stroke. Indeed, higher micro-
vessel density in the penumbra areas correlated with longer 
times of survival [7]. In order to be of benefit, increased 
microvessel density should persists in infarcted areas of the 
brain. In animal models, the long-term stability of ischaemia 
induced microvessels after middle cerebral artery occlusion 
(MCAO) show them leaky and transient. This newly formed 
blood vessels may serve to remove necrotic tissue and 
promote angiogenesis.  
Pathophysiology of Angiogenesis after Stroke 
  The permanent or transient middle cerebral artery occlu-
sion models (pMCAO and tMCAO) are the major animal 
models for studying changes in gene or protein expression 
after stroke [8]. In the tMCAO model, ischaemia is generated 
for a fixed, transient time and reperfusion is then allowed. 
The changes which occur, most usefully mimick situation 
which occur after stroke in humans. However, limited know-
ledge about the molecular mechanisms involved in tissue 
regeneration has been gained from animal experiments using 
the MCAO model which replicates, in many aspects, the 
neuropathological changes seen following stroke in humans 
[9]. In addition, only the ipsilateral side of the brain is affec-
ted by the ischemic damage, allowing collection of experi-
mental and reference control tissue from the same animal.  
  Angiogenesis and neurogenesis has been observed in the 
brains of patients who survived form several days to weeks 
after cerebral stroke and a positive correlation between 
microvessel density and patient survival was demonstrated 
[7]. Increased synthesis of angiogenic growth factors like 
FGF-2, PDGF, VEGF and its receptors was seen in the brain 
after stroke [7, 10, 11]. The molecules were up-regulated 
within hours of stroke and correlated with blood vessel 
growth in the penumbra region. The highest expression of 
molecules such as hyaluronidases, which degrade hyaluronan 
acid (HA) to an angiogenic low molecular weight form and 
its receptors on endothelial cells was seen in the acute phase 
of stroke, when remodelling may be occurring [12]. Analysis 
of ischemic brain tissue with techniques which are capable of 
studying multiple transcripts simultaneously can identify 
gene expression changes previously not known to be impli-
cated in ischemic pathophysiology, and evaluation of their 
physiological significance. This can lead to development of 
new targets for stroke therapy [13]. DNA microarray tech-
nology has provided tools to investigate the expression of 
thousands of genes in a single hybridization experiment. 
Several experimental studies have examined alteration of 
gene expression in the post-ischemic rat brain, using micro-
array technology [14-18] while promising results of blood 
genomic profiling in human stroke have been obtained in 
recent pilot studies [19, 20]. Until recently, gene expression 
profiling had not been applied to patients dying of ischaemic 
stroke, in part because human brain autopsies are not regu-
larly obtained. The majority of RNA transcripts and proteins 
in the human brain degrade only to a minor degree following 
death, thus making autopsy tissue a useful source for the 
isolation of nucleic acids and proteins [21]. In fact, previous 
studies evaluating the mRNA quality in human post-mortem 
brain tissue have demonstrated a minimal effect upon their 
overall relative stability within 24 hours of death [22-24]. 
Recently, Vikman and Edvinsson [25] investigated the gene 
expression in human middle cerebral artery (MCA) after 
ischaemia using human MCA samples 7-10 days post-stroke; 
however, they obtained their samples after a considerable 
delay of 2-3 days post-mortem and they focused mainly on 
mRNA expression of receptors. Critical comparison of gene 
expression profiles after stroke in humans with those in 
animal models should lead to a better understanding of the 
pathophysiology of brain ischaemia and will allow us to 
evaluate the usefulness of animal models in stroke research.  
  Pro-angiogenic factors have been described, being some 
of them the proinflammatory cytokines (IL-1beta, TNF-alfa), 
nitric oxide (NO), and growth factors (TGB-beta, PDGF, 
VEGT, FGF) that are also expressed after a ischemic process 
[2, 3, 26]. VEGF administration and VEGFR-1 modulation 
stimulates both neurogenesis and angiogenesis after a ische-
mic disease [27]. Recent studies in neonatal rodent stroke 
models suggest that recovery is due in part to upregulation of 
hypoxia-inducible factor-1-a and its downstream target, 
vascular endothelial growth factor. Vascular endothelial 
growth factor is upregulated after a hypoxic insult and is 
involved in neuronal survival, angiogenesis, and neuro-
genesis during the recovery process [28]. 
  Angiogenesis is directly linked to neurogenesis. The later 
needs new vasculature in order to survive for a longer time. 
Mechansisms of angiogenesis are similar to neurogenesis 
and both processes share common factors. All three pro-
cesses i.e. plasticity, neurogenesis and angiogenesis occur in 
adult brain as a response to injury but can be stimulated by 
additional cellular therapy.  
3. NEUROREPAIR: ANGIOGENESIS NEUROGENE-
SIS AND PLASTICITY  
Triggering Penumbra 
  Ischaemic stroke results from cessation of blood flow in a 
major cerebral vessel and leads to de-regulation of genes 
whose expression promotes ischemic neuronal death and 
subsequent neurological dysfunction [29, 30]. Under ische-
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energy metabolism fails, and severe reduction in mRNA and 
protein synthesis occurs in the ischemic core region. The 
tissue surrounding this area (peri-infarcted region) is able to 
maintain some functions such as ionic homeostasis and can 
be partially salvaged by blood recirculation (for a review see 
[2, 31]). The precise molecular mechanisms involved in 
ischemia-induced brain injury remain poorly understood. 
  The original definition of the ischaemic penumbra 
referred to areas of the brain that were damage but not yet 
dead, offering the promise that if proper therapies could be 
found, one could rescue brain tissue after stroke. Probably 
the most important part of early recovery after stroke is 
limited capacity of penumbra/infarct neurones to recover. It 
became more clear in the last years, that penumbra is not just 
passively dying over time. It is also actively recovering. In 
penumbra, partially depolarised tissue adjacent to the infarc-
ted core with reduced cerebral blood flow and increased 
oxygen extraction rate struggle for survival in a very limited 
time-window. This initial plasticity in majority contributes 
towards later neurogenesis, angiogenesis and final recovery. 
Penumbra is a principal target in acute phase of stroke. 
Understanding of each of the processes is a major challenge 
for future therapies in neuroreparation.  
  Many common pathways are triggered after stroke [32]. 
Possibly, the most important discovery is the biphasic nature 
of molecular signals in the penumbra in terms of injury 
versus repair [33]. This is the case for NMDA receptors or 
metalloproteinase (MMP) family. In the early phase after 
stroke these pathways may be detrimental, but in the con-
trary, in later phase are crucial for neuroblast migration and 
neurorepair [34-36].  
Neurogenesis 
  Neurogenesis, discovered only recently continues after 
the birth [37] and can be reactivated as a response to lesion 
[38]. Generation of new neurones from progenitors occurs in 
selected areas: subgranular zone of dentate gyrus, subven-
tricular zone of some cortical areas, substantia nigra and 
perinfarcted areas. Neurogenesis is controlled by intrinsic 
genetic mechanisms and growth factors but also ambiental 
factors are important like physical activity, etc. [39]. The 
leading process of the migrating neural progenitor cells 
(NPCs) is closely associated with blood vessels, suggesting 
that this interaction provides directional guidance to the 
NPCs. These findings suggest that blood vessels play an 
important role as a scaffold for NPCs migration toward the 
damaged brain region [40]. Close impact on neurogenesis is 
contribution of hypoxia-inducible factor-1alpha (HIF-
1alpha) to the therapeutic effect of neural stem cell (NSC) 
transplantation in cerebral ischemia. The relative efficacy of 
modified NSC to promote behavioral recovery was inves-
tigated in a rat model of stroke induced by a transient middle 
cerebral artery occlusion (MCAO). All animals showed 
functional improvement. Improvement was accelerated in 
animals receiving either NSC-Ad or Ad-HIF-1alpha, while 
improvement at all times between 7 days and 28 days post 
MCAO was significantly greater in animals transplanted 
with NSC-Ad-HIF-1alpha than for other treated animals. 
NSC-Ad-HIF-1alpha cells also increased the number of 
factor VIII-positive cells in the region of ischemic injury, 
indicating that HIF-1alpha expression can promote angio-
genesis. Gene-modified NSC expressing HIF-1alpha have 
therapeutic potential in ischemic stroke [41-43]. Neural stem 
cells (NSCs) persist in the forebrain subventricular zone 
(SVZ) within a niche containing endothelial cells. Evidence 
suggests that endothelial cells stimulate NSC expansion and 
neurogenesis. Experimental stroke increases neurogenesis 
and angiogenesis, but how endothelial cells influence stroke-
induced neurogenesis is unknown. SVZ neurospheres co-
cultured with endothelial cells generated more immature-
appearing neurons and oligodendrocytes, and astrocytes with 
radial glial-like/reactive morphology than controls. Oxygen 
glucose deprived endothelial cells stimulated neuroblast 
migration and yielded neurons with longer processes and 
more branching. These data indicate that intact and injured 
endothelial cells exert differing effects on NSCs, and suggest 
targets for stimulating regeneration after brain insults [44]. 
Plasticity 
  Plasticity is defined as anatomic and functional changes 
in the central nervous system (CNS) which result in better 
functional recovery [45, 46]. The mechanisms involved are: 
regulation of brain circuits and activation of parallel 
pathways in order to maintain lesioned function; activation 
of silent pathways; and synaptogenesis leading to formation 
of new connections [47]. 
  Acute brain lesions trigger diaschisis phenomena [48]. 
The diaschisis produces sudden loss of functions that are in 
areas remote to the injury but with anatomical connections to 
the damaged area. One of the mechanisms responsible for 
this depression of neuronal activity is glutamate excitoto-
xicity. The resolution of diaschisis contributes to later func-
tional recovery, and in that recovery is not only involved the 
ipsilateral hemisphere but also the contralateral, the cere-
bellum and the spinal cord. The time profile of the changes 
reflect different mechanisms. The unmasking of silent synap-
ses can strengthen existing neural circuits by modulating 
GABAergic mechanisms through rapid de-bottlenecking of 
the existing GABAergic inhibition. The long-term changes 
are based not only in unmasking the silent synapses but in 
axonal regeneration with creation and changes in shape, 
number and type of synapses [47]. Dendritic spines are ma-
jor postsynaptic targets of glutamatergic transmission in the 
adult brain and are subject to constant remodeling through 
the action of neurotransmitters, neurotrophic factors, newly 
synthesized synaptic proteins and gene expression [49]. 
Further, that one of the main determinants of synaptogenesis 
is training [50, 51]. 
4. ATHEROSCLEROSIS-CARDIOEMBOLISM-
ANGIOGENESIS 
  Formation of unstable plaques is a key mechanism 
leading to atherothrombosis, the major cause for ischaemic 
stroke, myocardial infarction and peripheral arterial disease. 
Patients who have symptomatic thrombosis in one vascular 
bed are at increased risk of disease in other beds. However, 
the development of the disease in carotid, coronary and 
peripheral arteries may have different pathophysiology 
suggesting that more complex treatment protocols may have 
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locations. Important developmental features of coronary and 
carotid plaque development and genetic differences are seen 
which contribute to plaque development as well as in the 
deregulation of gene and protein expression and cellular 
signal transduction activity of active cells in regions sus-
ceptible to thrombosis. Differences between carotid and 
coronary artery plaque development might help to explain 
the nature of embolic mechanisms of stroke [52]. 
  Clinical signs of atherosclerosis, such as heart attack and 
stroke, are often caused by rupture of the cap of an athero-
sclerotic plaque, with thrombus formation as a consequence. 
The risk of rupture depends on the formation of microvessels 
(angiogenesis) in the plaque. The fragility of the micro-
vascular endothelium causes hyperpermeability, which leads 
to intraplaque haemorrhage. Angiogenesis is stimulated by 
hypoxia, oxidative stress and the production of hypoxia-
inducible transcription factors. Hypoxia is primarily caused 
by increased oxygen consumption of inflammatory cells, 
while plaque thickness, which reduces oxygen diffusion, 
contributes to a limited extent. A vicious circle of hypoxia, 
deletorious angiogenesis and inflammation occurs deep in 
the plaque, which enhances plaque growth and the risk of 
plaque rupture. By non-invasive imaging of plaque hypoxia 
and angiogenesis, plaques at risk of rupture may be iden-
tified. Therapeutic interventions for plaque angiogenesis and 
hypoxia require further investigation [53]. 
5. MODELING THE NEUROVASCULAR NICHE 
  Therapeutic strategies in stroke have been developed 
with two main aims: restoration of cerebral flow and the 
minimization of the deleterious effects of ischemia on 
neurons. Intense research spanning over the last two decades 
has witnessed significant therapeutic advances in the form of 
carotid endarterectomy, thrombolytics, mechanical throm-
bectomy, anticoagulant therapy, antiplatelet agents, neuro-
protective agents, and treating associated risk factors such as 
hypertension, diabetes and hyperlipidemia. However, the 
search for an effective neuroprotectant remains frustrating, 
and the current therapeutic protocols remain suboptimal. Till 
date only one FDA-approved drug is available for ischemic 
stroke; i.e., the serine protease tissue-type plasminogen acti-
vator (tPA), utility of which is limited by short therapeutic 
window [54]. 
Cellular Therapy 
  The main aim of cell therapy is to mimic neurore-
paration processes that naturally occur in the brain. At 
experimental level in animal models of cerebral ischemia, 
three types of human cells have been used for transplants: 
neural progenitor cells derived from fetal tissue, neural cell 
lines, stromal cells and hematopoietic progenitor/endothelial 
derived from bone marrow, umbilical cord blood, peripheral 
blood or adipose tissue [55]. Recent data suggest that bone–
marrow stromal cells from stroke rats (Isch-BMSCs) are 
superior to normal rats (Nor-BMSCs) for the neurores-
torative treatment of stroke, which may be mediated by the 
enhanced trophic factor and angiogenic characteristics of 
Isch-BMSCs [56].Currently there are few completed clinical 
trials in patients with ischemic stroke. The treatment has 
been shown safe and without side effects although functional 
improvement of the treated group compared to control is 
unclear [57]. The reality is that there are still many issues to 
resolve before cell therapy becomes a therapeutic option to 
treat stroke. 
Old or New Pharmacology 
  In our clinical practice, we use two basic methods of 
treatment, preventive treatment based on long-term use of 
antiplatelet or anticoagulant to reduce the risk of a new 
event, or fibrinolytic therapy as an acute treatment of stroke. 
However, less than 2% of patients receive the latter 
treatment. In last years researchers are working hard in 
search of neuroprotective agents in the acute phase of stroke 
and in the search for neurorepair drugs to use in the chronic 
phase. While the therapeutic window of neuroprotective 
drugs is small (0-8 hours at best), the window of neruorepair 
is much wider (days, weeks or even months). 
  Drug therapy is oriented towards stimulating endogenous 
neurorepair processes. In the absence of succesful drug 
therapy, rehabilitation is the most useful treatment for impro-
ving functional recovery after stroke [51, 58]. As a general 
rule, most neurorepair drug trials generally showed that 
drugs are safe, but the number of patients included is small 
and there is no contrasting results that allow recommen-
dation for larger population [58-60]. Drugs affecting nor-
adrenergic transmission such as amphetamine, methyl-
phenidate or levodopa have been tested, or drugs that act at 
nitrergic level, as donors of NO, sildenafil or analogues of 
cyclic GMP (disputed by the dual role of NO in neuro-
genesis). Other drugs that have been tested are selective 
inhibitors of serotonin reuptake, myelin inhibitors such as 
anti-Nogo-A (myelin prevents axonal growth and limits 
synaptic plasticity), botulinum toxin, erythropoietin or the 
hopeful statins and citicoline 
  More recent studies demonstrated beneficial effects of G-
CSF treatment (granulocyte colony-stimulating factor) in 
various CNS disease. Possible mechanisms underlying this 
activity are neuroprotection, anti-apoptosis, angiogenesis and 
anti-inflammation. In combination with G-CSF-induced 
leukocytosis, increased peripheral neutrophils could aggre-
gate within microvasculature and additionally impair blood 
perfusion of the ischemic tissue. Authors demonstrated that 
G-CSF deficiency leads to increased infarct volumes, 
whereas G-CSF substitution revokes detrimental effects by 
reducing lesion size and enhancing neurological outcome 
compared to untreated animals. Administration of G-CSF is 
accompanied by significant increase of circulating neutro-
phils 2 days post-ischemia but leukocytosis is restricted to 
the vessel compartment and has no deleterious effect on 
lesion formation and functional recovery. These observations 
are likely to be important for therapeutic targeting of G-CSF-
mediated neuroprotection in stroke [61, 62]. Another new 
possible neuroprotective target is activated protein C (APC). 
In stroke models, promotes postischemic neovascularization 
and neurogenesis. Mice treated with single-dose or multidose 
APC, compared with vehicle, showed significantly improved 
motor function on all tests. In the single-dose and multidose 
APC treatment groups, at 7 days after treatment, lesion 
volume was significantly decreased by 30% and 50%, 
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increased new blood vessel formation. Multidose APC also 
promoted proliferation of neuroblasts in the subventricular 
zone (SVZ) and their migration from the SVZ to the 
perilesional area. In conclusion activated protein C improves 
functional outcome and is neuroprotective. It also promotes 
angiogenesis and survival and migration of neuroblasts from 
the SVZ to the perilesional area, but the exact role of these 
brain repair mechanisms remains to be determined [63].  
Therapeuctic Potential of Angiogenesis 
  The origin of newly formed vessels and the pathogenic 
role of
  neovascularization and neurogenesis are important 
unresolved issues in our understanding
  of the mechanisms 
after stroke. Furthermore, the lack
 of consensus concerning 
the contribution of angiogenesis has
  serious practical 
implications because it continues to place
 a question mark on 
the use of angioneurins to treat stroke. Clearly, more experi-
mental
 work is needed to address these questions and illumi-
nate some of the key outstanding problems.
  Among the 
currently available treatments, only statins, showed pleiotro-
pic pro- and antiangiogenic properties. The currently 
available data from both animal and human studies regarding 
the effects of statins on angiogenesis demonstrate that statins 
are safe, orally available agents that may acquire novel 
therapeutic indications through their angiogenic modulating 
effects [64]. Combination of sub-therapeutic doses of 
Simvastatin and bone marrow stromal cells (BMSCs) have 
additive effects in stroke therapy, improves neurological 
outcome, enhances angiogenesis and arteriogenesis, and 
increases the number of engrafted-BMSCs in the ischemic 
brain. Simvastatin significantly increased stromal cell-
derived factor-1 (SDF1) expression in the ischemic brain and 
chemokine (CXC motif) receptor-4 (CXCR4) in BMSCs, 
and increased BMSC migration to RBMECs and astrocytes. 
Thus, combination treatment of stroke upregulates the 
SDF1/CXCR4 axis and enhances BMSC migration into the 
ischemic brain, amplifies arteriogenesis and angiogenesis, 
and improves functional outcome after stroke [65]. 
  Controlled reperfusion and re-establishment of the local 
micro-circulation, together with reduction in both immediate 
and delayed neuronal apoptosis, after stroke, could improve 
neuronal survival and organization, and ultimately patient 
recovery [66]. Cell-based angiogenic therapy after cerebral 
ischaemia not only induces angiogenesis but improves 
neuronal regeneration [6]. Investigation into the factors that 
promote angiogenesis (the growth of new blood vessels from 
pre-existing ones) and neuroprotection, which over a period 
of at least a few days might help limit neuronal injury, might 
identify a target for therapeutic intervention in stroke.  
  In ischaemic penumbra, normal cell function might be 
retained by restoration of the blood flow to such areas, and 
hence the penumbra is salvageable by therapeutic interven-
tion [2]. Neurotrophic factors, for instance nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF) and 
basic fibroblast growth factor (FGF- 2) are involved in the 
regulation of nerve cell survival and differentiation during 
development and in the functional maintenance of adult 
neurones [67, 68]. FGF-2 is also thought to be important for 
regeneration and restoration of function in pathophysiolo-
gical situations, such as chemical neurotoxicity, mechanical 
trauma and brain ischaemia and more specifically can protect 
cortical synaptic terminals from amyloid and oxidative 
stress-induced impairment of glucose, glutamate transport 
and mitochondrial function. The major progress in neurovas-
cular signalling was discovery that many molecules affect 
the development of both the nervous system and the vascular 
system [69]. Some classical angiogenic factors described 
above, have originated from the nervous system and some of 
the classical neurotrophic factors have also angiogenic 
properties. These molecules that have such dual neurovas-
cular properties are currently called angioneurins and are 
divided in three major groups: (1) angioneurins discovered 
through their neuronal effects (NGF, BDNF, NT3, NT4), (2) 
angioneurins discovered as angiogenic factors (VEGF, 
PDGF, ANG), (3) other angioneurins that have pleiotrophic 
effects (TGF, EPO, FGF2, HGF, EGF, IGF1, PGRN) [69]. 
An important property of angioneurins is their neuropro-
tective activity. They enhance neurogenesis, modulate 
synaptic plasticity, have positive effect on neurite outgrowth, 
branching and elimination making them ideal neuropro-
tective Drugs Madri JA et al., [70] using in vivo and in vitro 
murine models of sublethal hypoxia mimicked the variable 
responses observed in the human population and correlated 
differences in baseline and hypoxia-induced induction of 
HIF-1alpha and several downstream signaling components 
including BDNF, VEGF, SDF-1, TrkB, Nrp-1, CXCR4 and 
NO with differences in survival as well as endothelial cell 
and neural stem cell survival and proliferation, providing 
insight into this important and timely problem and sugges-
ting that optimization of expression levels of some or all of 
these signaling components may have the potential of 
maximizing recovery following CNS injury [71]. New 
question raised recently is whether patients with different 
risk factors may have variable responses to proangiogenic 
therapies. Indeed, the development of collateral vessels, 
which is important to prevent ischemic tissues from cell 
death, is impaired in patients with diabetes mellitus. The 
process is regulated by many positive and negative factors. 
Compared with the controls, the diabetes groups have lower 
vessel density, more expression of angiostatin, and lower 
level of VEGF. These results showed angiogenesis is defi-
cient in diabetes groups after ischemical reperfusion (I/R) 
injury. And the possible mechanism is hyperglycemia atte-
nuates neovascularization by downregulating proliferative 
properties of VEGF and upregulating of negative properties 
of angiostatin [72]. Novel emerging target is beta1 integrin, a 
cell surface molecule that is critical for endothelial cell 
adhesion, migration and survival during angiogenesis. beta1 
integrin plays important roles in neurovascular remodelling 
and functional outcomes following stroke, and that targeting 
the beta1 integrin signalling may provide a novel strategy for 
modulating angiogenesis in ischemic stroke and other 
pathological conditions [73]. 
Biomaterials for Neurorepair 
  Biomaterials for promoting brain protection, repair and 
regeneration are new hot target [74]. Recently developed 
biomaterials can enable and increase the target delivery of 
drugs or therapeutic proteins to the brain, allow cell or tissue 
transplants to be effectively delivered to the brain and help to 
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used to promote regeneration and to repair damaged neuro-
nal pathways in combination with stem cell therapies. These 
new approaches are gaining clear importance because nano-
technology allows better control over material-cell inter-
actions that induce specific developmental processes and 
cellular respones including differentiation, migration and 
outgrowth.  
6. CONCLUSIONS 
  Dissection of mechanisms and molecular pathways that 
mediate neuronal death should bring major advances in 
successful neuroprotective therapies. However, this purely 
neuronal approach failed in the past decades [31]. Neurones, 
as the most important cells in the CNS are integrated in a 
complex network of multiple cell types, including neurones, 
astrocytes, oilgodendrocytes, microglia, endothelial cells and 
pericytes comprising the cerebral microvasculature as well as 
matrix with axonal compartments in white matter [75]. The 
NINDS stroke progress review group identified the “neuro-
vascular unit” as a conceptual model that emphasizes cell-
cell and cell-matrix signaling between all the cells of the 
brain (NINDS, 2002). Further, integration between neuronal 
and vascular components considers the brain from the 
functional perspective. This is important for future research 
with neurovascular unit as a therapeutical target. 
  The major challanges for future lie in the uncoupling of 
biphasic response to ischaemia and dual effects of many 
molecules which are implicated in the initial tissue damage. 
Advances in molecular biology, genetic engineering, proteo-
mics and genomics are increasing our understanding of 
disease processes and may soon allow us to treat or reverse 
the underlying pathology. At the same time, advances in cell-
based therapeutics, regenerative medicine and tissue engi-
neering are raising the possibility of replacing damaged 
neurons or coaxing neuronal circuits to regenerate. Here, 
biomaterials (i.e. materials that are used and adapted for a 
medical application and thus intended to interact with as 
biological system) have become increasingly important in 
the development of drug delivery systems and tissue engi-
neering approaches. In the near future, they may play a key 
role in overcoming the inherent insufficiency of protection, 
repair and regeneration of the brain.  
REFERENCES 
[1]  Kim Y, Kim JH, Nam YJ, et al. Klotho is a genetic risk factor for 
ischemic stroke caused by cardioembolism in Korean females. 
Neurosci Lett 2006; 407(3): 189-94. 
[2]  Slevin M, Kumar P, Gaffney J, Kumar S, Krupinski J. Can 
angiogenesis be exploited to improve stroke outcome? Mechanisms 
and therapeutic potential. Clin Sci (Lond) 2006; 111(3): 171-83. 
[3]  Lizasoain I, Moro MA, Fernández-López D, Pradillo JM, Sobrino 
T, Castillo J. Plasticidad, neurogénesis y angiogénesis: Medica 
Books; 2007. 
[4]  Zhang ZG, Chopp M. Neurorestorative therapies for stroke: 
underlying mechanisms and translation to the clinic. Lancet Neurol 
2009; 8(5): 491-500. 
[5]  Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin 
receptor in neurogenesis and post-stroke recovery. J Neurosci 
2006; 26(4): 1269-74. 
[6]  Taguchi A, Soma T, Tanaka H, et al. Administration of CD34+ 
cells after stroke enhances neurogenesis via angiogenesis in a 
mouse model. J Clin Invest 2004; 114(3): 330-8. 
[7]  Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Role of 
angiogenesis in patients with cerebral ischemic stroke. Stroke 
1994; 25(9): 1794-8. 
[8]  Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z, Kikuchi H. 
Evaluation of MCAO stroke models in normotensive rats: 
standardized neocortical infarction by the 3VO technique. Exp 
Neurol 2003; 182(2): 261-74. 
[9]  Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible 
middle cerebral artery occlusion without craniectomy in rats. 
Stroke 1989; 20(1): 84-91. 
[10]  Krupinski J, Kaluza J, Kumar P, Kumar S. Immunocytochemical 
studies of cellular reaction in human ischemic brain stroke MAB 
anti-CD68 stains macrophages, astrocytes and microglial cells in 
infarcted area. Folia Neuropathol 1996; 34(1): 17-24. 
[11]  Krupinski J, Issa R, Bujny T, et al. A putative role for platelet-
derived growth factor in angiogenesis and neuroprotection after 
ischemic stroke in humans. Stroke 1997; 28(3): 564-73. 
[12]  Al Qteishat A, Gaffney JJ, Krupinski J, Slevin M. Hyaluronan 
expression following middle cerebral artery occlusion in the rat. 
Neuroreport 2006; 17(11): 1111-4. 
[13]  Lippoldt A, Reichel A, Moenning U. Progress in the identification 
of stroke-related genes: emerging new possibilities to develop 
concepts in stroke therapy. CNS Drugs 2005; 19(10): 821-32. 
[14]  Soriano MA, Tessier M, Certa U, Gill R. Parallel gene expression 
monitoring using oligonucleotide probe arrays of multiple 
transcripts with an animal model of focal ischemia. J Cereb Blood 
Flow Metab 2000; 20(7): 1045-55. 
[15]  Jin K, Mao XO, Eshoo MW, et al. Microarray analysis of 
hippocampal gene expression in global cerebral ischemia. Ann 
Neurol 2001; 50(1): 93-103. 
[16]  Kim JB, Piao CS, Lee KW, et al. Delayed genomic responses to 
transient middle cerebral artery occlusion in the rat. J Neurochem 
2004; 89(5): 1271-82. 
[17]  Lu XC, Williams AJ, Yao C, et al. Microarray analysis of acute 
and delayed gene expression profile in rats after focal ischemic 
brain injury and reperfusion. J Neurosci Res 2004; 77(6): 843-57. 
[18]  Ford G, Xu Z, Gates A, Jiang J, Ford BD. Expression Analysis 
Systematic Explorer (EASE) analysis reveals differential gene 
expression in permanent and transient focal stroke rat models. 
Brain Res 2006; 1071(1): 226-36. 
[19]  Moore DF, Li H, Jeffries N, et al. Using peripheral blood 
mononuclear cells to determine a gene expression profile of acute 
ischemic stroke: a pilot investigation. Circulation 2005; 111(2): 
212-21. 
[20]  Tang XW, Wu DP, Sun AN, Zhu ZL, Chang WR, Ruan CG. 
Quantitative analysis of donor chimerism in adoptive immuno-
therapy following allogeneic hematopoietic stem cell transplan-
tation. Zhonghua Nei Ke Za Zhi 2006; 45(5): 359-62. 
[21]  Hynd MR, Lewohl JM, Scott HL, Dodd PR. Biochemical and 
molecular studies using human autopsy brain tissue. J Neurochem 
2003; 85(3): 543-62. 
[22]  Schramm M, Falkai P, Tepest R, et al. Stability of RNA transcripts 
in post-mortem psychiatric brains. J Neural Transm 1999; 106(3-
4): 329-35. 
[23]  Castensson A, Emilsson L, Preece P, Jazin EE. High-resolution 
quantification of specific mRNA levels in human brain autopsies 
and biopsies. Genome Res 2000; 10(8): 1219-29. 
[24]  Almeida A, Paul Thiery J, Magdelenat H, Radvanyi F. Gene 
expression analysis by real-time reverse transcription polymerase 
chain reaction: influence of tissue handling. Anal Biochem 2004; 
328(2): 101-8. 
[25]  Vikman P, Edvinsson L. Gene expression profiling in the human 
middle cerebral artery after cerebral ischemia. Eur J Neurol 2006; 
13(12): 1324-32. 
[26]  Turu MM, Slevin M, Matou S, et al. C-reactive protein exerts 
angiogenic effects on vascular endothelial cells and modulates 
associated signalling pathways and gene expression. BMC Cell 
Biol 2008; 9: 47. 
[27]  Beck H, Raab S, Copanaki E, et al. VEGFR-1 signaling regulates 
the homing of bone marrow-derived cells in a mouse stroke model. 
J Neuropathol Exp Neurol 2010; 69(2): 168-75. 
[28]  Shimotake J, Derugin N, Wendland M, Vexler ZS, Ferriero DM. 
Vascular endothelial growth factor receptor-2 inhibition promotes 
cell death and limits endothelial cell proliferation in a neonatal 
rodent model of stroke. Stroke 2010; 41(2): 343-9. 244    Current Cardiology Reviews, 2010, Vol. 6, No. 3  Padros et al. 
[29]  Slevin M, Krupinski J, Kumar P, Gaffney J, Kumar S. Gene 
activation and protein expression following ischaemic stroke: 
strategies towards neuroprotection. J Cell Mol Med 2005; 9(1): 85-
102. 
[30]  Mitsios N, Gaffney J, Kumar P, Krupinski J, Kumar S, Slevin M. 
Pathophysiology of acute ischaemic stroke: an analysis of common 
signalling mechanisms and identification of new molecular targets. 
Pathobiology 2006; 73(4): 159-75. 
[31]  Schaller B, Graf R. Cerebral ischemia and reperfusion: the 
pathophysiologic concept as a basis for clinical therapy. J Cereb 
Blood Flow Metab 2004; 24(4): 351-71. 
[32]  Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and 
opportunities in stroke. Nat Rev Neurosci 2003; 4(5): 399-415. 
[33]  Lo EH. Experimental models, neurovascular mechanisms and 
translational issues in stroke research. Br J Pharmacol 2008; 153 
Suppl 1: S396-405. 
[34]  Ikonomidou C, Stefovska V, Turski L. Neuronal death enhanced by 
N-methyl-D-aspartate antagonists. Proc Natl Acad Sci USA 2000; 
97(23): 12885-90. 
[35]  Arvidsson A, Kokaia Z, Lindvall O. N-methyl-D-aspartate 
receptor-mediated increase of neurogenesis in adult rat dentate 
gyrus following stroke. Eur J Neurosci 2001; 14(1): 10-8. 
[36]  Zhao BQ, Wang S, Kim HY, et al. Role of matrix metallo-
proteinases in delayed cortical responses after stroke. Nat Med 
2006; 12(4): 441-5. 
[37]  Altman J. Autoradiographic investigation of cell proliferation in the 
brains of rats and cats. Anat Rec 1963; 145: 573-91. 
[38]  Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in 
the adult human hippocampus. Nat Med 1998; 4(11): 1313-7. 
[39]  Kokaia Z, Lindvall O. Neurogenesis after ischaemic brain insults. 
Curr Opin Neurobiol 2003; 13(1): 127-32. 
[40]  Kojima T, Hirota Y, Ema M, et al. Subventricular zone-derived 
neural progenitor cells migrate along a blood vessel scaffold 
toward the post-stroke striatum. Stem Cells 2010; 28: 545-54. 
[41]  Shi H. Hypoxia inducible factor 1 as a therapeutic target in 
ischemic stroke. Curr Med Chem 2009; 16(34): 4593-600. 
[42]  W u W , C hen X,  Hu C,  L i J,  Yu Z ,  C ai  W .  T r anspl ant at i on of  
neural stem cells expressing hypoxia-inducible factor-1alpha (HIF-
1alpha) improves behavioral recovery in a rat stroke model. J Clin 
Neurosci 2010; 17(1): 92-5. 
[43]  Correia SC, Moreira PI. Hypoxia-inducible factor 1: a new hope to 
counteract neurodegeneration? J Neurochem 2010; 112(1): 1-12. 
[44]  Plane JM, Andjelkovic AV, Keep RF, Parent JM. Intact and injured 
endothelial cells differentially modulate postnatal murine forebrain 
neural stem cells. Neurobiol Dis 2010; 37(1): 218-27. 
[45]  Johansson BB. Regeneration and plasticity in the brain and spinal 
cord. J Cereb Blood Flow Metab 2007; 27(8): 1417-30. 
[46]  Lee RG, van Donkelaar P. Mechanisms underlying functional 
recovery following stroke. Can J Neurol Sci 1995; 22(4): 257-63. 
[47]  Calabresi P, Centonze D, Pisani A, Cupini L, Bernardi G. Synaptic 
plasticity in the ischaemic brain. Lancet Neurol 2003; 2(10): 622-9. 
[48]  Carmichael ST, Tatsukawa K, Katsman D, Tsuyuguchi N, 
Kornblum HI. Evolution of diaschisis in a focal stroke model. 
Stroke 2004; 35(3): 758-63. 
[49]  Kawamata T, Dietrich WD, Schallert T, et al. Intracisternal basic 
fibroblast growth factor enhances functional recovery and up-
regulates the expression of a molecular marker of neuronal 
sprouting following focal cerebral infarction. Proc Natl Acad Sci 
USA 1997; 94(15): 8179-84. 
[50]  Johansson BB, Ohlsson AL. Environment, social interaction, and 
physical activity as determinants of functional outcome after 
cerebral infarction in the rat. Exp Neurol 1996; 139(2): 322-7. 
[51]  Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced 
movement therapy on upper extremity function 3 to 9 months after 
stroke: the EXCITE randomized clinical trial. JAMA 2006; 
296(17): 2095-104. 
[52]  Slevin M, Kumar P, Wang Q, et al. New VEGF antagonists as 
possible therapeutic agents in vascular disease. Expert Opin 
Investig Drugs 2008; 17(9): 1301-14. 
[53]  Sluimer JC, Daemen MJ. New understanding of the onset of 
atherosclerosis--angiogenesis and hypoxia play a crucial role. Ned 
Tijdschr Geneeskd 2009; 153: A847. 
[54]  Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of 
acute ischemic stroke: An overview with emphasis on therapeutic 
significance beyond thrombolysis. Pathophysiology 2010; 17:197-
218. 
[55]  Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation 
therapy for stroke. Stroke 2007; 38(2 Suppl): 817-26. 
[56]  Zacharek A, Shehadah A, Chen J, et al. Comparison of bone 
marrow stromal cells derived from stroke and normal rats for 
stroke treatment. Stroke 2010; 41: 524-30. 
[57]  Kondziolka D, Wechsler L, Goldstein S, et al. Transplantation of 
cultured human neuronal cells for patients with stroke. Neurology 
2000; 55(4): 565-9. 
[58]  Dobkin BH. Strategies for stroke rehabilitation. Lancet Neurol 
2004; 3(9): 528-36. 
[59]  Chen J, Chopp M. Neurorestorative treatment of stroke: cell and 
pharmacological approaches. NeuroRx 2006; 3(4): 466-73. 
[60]  Hesse S. Recovery of gait and other motor functions after stroke: 
novel physical and pharmacological treatment strategies. Restor 
Neurol Neurosci 2004; 22(3-5): 359-69. 
[61]  Strecker JK, Sevimli S, Schilling M, et al. Effects of G-CSF 
treatment on neutrophil mobilization and neurological outcome 
after transient focal ischemia. Exp Neurol 2010; 222: 108-13. 
[62]  Lanfranconi S, Locatelli F, B Corti S, et al. Growth factors in 
ischemic stroke. J Cell Mol Med 2009, in press 
[63]  Petraglia AL, Marky AH, Walker C, Thiyagarajan M, Zlokovic 
BV. Activated protein C is neuroprotective and mediates new 
blood vessel formation and neurogenesis after controlled cortical 
impact. Neurosurgery 2010; 66(1): 165-71; discussion 71-2. 
[64]  Elewa HF, El-Remessy AB, Somanath PR, Fagan SC. Diverse 
effects of statins on angiogenesis: new therapeutic avenues. 
Pharmacotherapy 2010; 30(2): 169-76. 
[65]  Cui X, Chopp M, Zacharek A, et al. Chemokine, vascular and 
therapeutic effects of combination Simvastatin and BMSC 
treatment of stroke. Neurobiol Dis 2009; 36(1): 35-41. 
[66]  Shin HK, Dunn AK, Jones PB, Boas DA, Moskowitz MA, Ayata 
C. Vasoconstrictive neurovascular coupling during focal ischemic 
depolarizations. J Cereb Blood Flow Metab 2006; 26(8): 1018-30. 
[67]  Chao MV. Trophic factors: An evolutionary cul-de-sac or door into 
higher neuronal function? J Neurosci Res 2000; 59(3): 353-5. 
[68]  Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal 
development and function. Annu Rev Neurosci 2001; 24: 677-736. 
[69]  Zacchigna S, Ruiz de Almodovar C, Carmeliet P. Similarities 
between angiogenesis and neural development: what small animal 
models can tell us. Curr Top Dev Biol 2008; 80: 1-55. 
[70]  Madri JA. Modeling the neurovascular niche: implications for 
recovery from CNS injury. J Physiol Pharmacol 2009; 60 Suppl 4: 
95-104. 
[71]  Calvert JW, Lefer DJ. Clinical translation of nitrite therapy for 
cardiovascular diseases. Nitric Oxide 2010; 22: 91-7. 
[72]  Zhu M, Bi X, Jia Q, Shangguan S. The possible mechanism for 
impaired angiogenesis after transient focal ischemia in type 2 
diabetic GK rats: Different expressions of angiostatin and vascular 
endothelial growth factor. Biomed Pharmacother 2010; 64: 208-13. 
[73]  Lathia JD, Chigurupati S, Thundyil J, et al. Pivotal role for beta-1 
integrin in neurovascular remodelling after ischemic stroke. Exp 
Neurol 2010; 221(1): 107-14. 
[74]  Orive G, Anitua E, Pedraz JL, Emerich DF. Biomaterials for 
promoting brain protection, repair and regeneration. Nat Rev 
Neurosci 2009; 10(9): 682-92. 
[75]  Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial intera-
ctions at the blood-brain barrier. Nat Rev Neurosci 2006; 7(1): 41-
53. 
 
 
Received: April 10, 2010  Revised: April 10, 2010             Accepted: May 25, 2010 
 